ATAI News and Press, ATAI Life Sciences N.V. From 09/27/22

- atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess the safety and tolerability of orally administered EMP-01 in 32 healthy volunteers ...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 –  Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminali...

The following slide deck was published by Atai Life Sciences N.V. in conjunction with this event. For further details see: ATAI Life Sciences (ATAI) Investor Presentation - Slideshow

NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever.  According to a National Institute of Health survey, the amount of people between age 19 to 30 who repor...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perce...

To talk about company resilience in the psychedelics industry is a bit premature. After all, most of the more prominent companies didn’t open their doors until 2016 or later. But it’s the perfect time to build a foundation for resilience while they look to a future o...

What some thought could have been the start of a meme stock rally for MindMed ( NASDAQ: MNMD ) appears to have ended, just one day after it began. After closing up 36% on Thursday, the psychedelic drug treatment company is flat in Friday morning trading. In Thursda...

MindMed, which is up 71% in Thursday premarket trading, appears to be the latest beneficiary of the meme stock craze. The company, which is developing psychedelic drug treatments, closed up 10% Wednesday. A recent story in the Financial Times about US college s...

Atai Life Sciences N.V. (ATAI) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Stephen Bardin – Deputy Chief Financial Officer Florian Brand – Chief Executive Officer ...